About

Developmental and epileptic encephalopathies are severe seizure disorders that begin in infancy or childhood, often causing developmental delays, cognitive impairment, and frequent, hard-to-control seizures. Relutrigine is a selective sodium channel blocker that targets overactive SCN2A and SCN8A proteins, which can trigger excessive electrical activity in the brain. By calming these hyperactive channels, relutrigine may reduce seizure frequency and potentially improve developmental outcomes for affected children.